Brexpiprazole |
OPC-34712 |
223366007 |
7672 |
7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE |
2(1H)-QUINOLINONE, 7-(4-(4-BENZO(B)THIEN-4-YL-1-PIPERAZINYL)BUTOXY)- |
D10309 |
HY-15780 |
BC600277 |
AK171366 |
CS-2108 |
AKOS025291100 |
OPC 34712 |
OPC34712 |
ZKIAIYBUSXZPLP-UHFFFAOYSA-N |
SCHEMBL14772509 |
BREXPIPRAZOLE (JAN/USAN/INN) |
SCHEMBL1037592 |
GTPL7672 |
2J3YBM1K8C |
REXULTI (TN) |
7-{4-(4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL)BUTOXY}QUINOLIN-2(1H)-ONE |
7-(4-(4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL)BUTOXY)QUINOLIN-2(1H)-ONE |
7-[4-[4-(1-BENZOTHIOPHEN-4-YL)PIPERAZIN-1-YL]BUTOXY]-1H-QUINOLIN-2-ONE |
7-(4-(4-(BENZO[B]THIOPHEN-4-YL)PIPERAZIN-1-YL)BUTOXY)QUINOLIN-2(1H)-ONE |
BREXPIPRAZOLE {USAN] |
BREXPIPRAZOLE [USAN] |
UNII-2J3YBM1K8C |
913611-97-9 |
11978813 |
Rexulti |
DB09128 |
Drug Categories | sulfur compounds |
Drug Categories | serotonin agents |
Drug Categories | quinolines |
Drug Categories | psycholeptics |
Drug Categories | physiological effects of drugs |
Drug Categories | pharmacologic actions |
Drug Categories | organic chemicals |
Drug Categories | neurotransmitter agents |
Drug Categories | nervous system |
Drug Categories | molecular mechanisms of pharmacological action |
Drug Categories | inorganic chemicals |
Drug Categories | hyperglycemia-associated agents |
Drug Categories | heterocyclic compounds, 2-ring |
Drug Categories | heterocyclic compounds, 1-ring |
Drug Categories | heterocyclic compounds |
Drug Categories | dopamine agonists |
Drug Categories | dopamine agents |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 cyp2d6 substrates |
Drug Categories | chemical actions and uses |
Drug Categories | central nervous system depressants |
Drug Categories | antipsychotic agents |
Drug Categories | alpha1 antagonists |
Drug Groups | approved |
Drug Type | small molecule |
FDA Approval | not approved |
Drug Class | small molecule |
Drug Indications | antidepressant |
partial agonist |
agonist |
Trial Name | OPC-34712 |
Novel drug target | Established target |
Mechanism of Interaction | Dopamine D2 receptor partial agonist |
partial agonist |
agonist |
Mechanism of Interaction | Serotonin 1a (5-HT1a) receptor partial agonist |
Direct Interaction | yes |
Trial Name | OPC-34712 |
antagonist |
Mechanism of Interaction | Serotonin 2a (5-HT2a) receptor antagonist |
Direct Interaction | yes |
Trial Name | OPC-34712 |
antagonist |
antagonist |
n/a |
Trial Name | OPC-34712 |
Novel drug target | Established target |
n/a |
BREXPIPRAZOLE | DrugBank Drug Name |
913611-97-9 | CAS Number |
Rexulti | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | alpha1 antagonists |
Drug Indications | antidepressant |
Drug Class | small molecule |
FDA Approval | not approved |
BREXPIPRAZOLE | pubchem_primary_name |
11978813 | PubChem CID |
913611-97-9 | Drug Synonym |
BREXPIPRAZOLE | GuideToPharmacology Ligand Name |
223366007 | PubChem Drug SID |